Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:51:04.349Z.
Calculation as of: 2026-10-06T12:51:04.349Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4980e4284b6230c79d3dcd5f09fe919c7c05eb80d65ab6e095ba480293e97312
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Canton Strategic Holdings Inc
Market Cap
$179.70M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.12M
Price/OCF Ratio
N/A
TTM Avg
32.12
3Y Avg
27.16
5Y Avg
27.16
Market Cap
$174.17M
Price/OCF Ratio
N/A
TTM Avg
357.25
3Y Avg
357.25
5Y Avg
357.25
Market Cap
$173.04M
Price/OCF Ratio
N/A
TTM Avg
193.13
3Y Avg
193.13
5Y Avg
37.46
Market Cap
$172.99M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.97M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$162.82M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $179.70M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $184.12M | N/A | 32.12 | 27.16 | 27.16 |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | N/A | 357.25 | 357.25 | 357.25 |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | N/A | 193.13 | 193.13 | 37.46 |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $160.82M | N/A | 113.17 | 139.63 | 64.33 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
